Asia-Pacific Next Generation Sequencing (NGS) Market (2025-2032)
The Asia-Pacific Next Generation Sequencing (NGS) Market is expected to grow at a CAGR of 16.9% from 2025 to 2032 to reach $6.38 billion by 2032.
- Published
- Jan 2025
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MRHC - 1041039
- Base year
- 2024
- 2032 · FORECAST
- $6.38B
- 2032
- $6.38B
- CAGR 2025–2032
- 16.9%
2024 baseline · 2025–2032 forecast at 16.9% CAGR · hover a bar for the value
Key highlights
The Asia-Pacific Next Generation Sequencing (NGS) Market is expected to grow at a CAGR of 16.9% from 2025 to 2032 to reach $6.38 billion by 2032.
The consumables segment is expected to account for the largest share of the Asia–Pacific NGS market by offering.
The targeted genome sequencing segment is expected to account for the largest share of the NGS market in 2025.
The sequencing by synthesis segment is expected to account for the largest share of the Asia–Pacific NGS market.
The pharmaceutical & biotechnology segment is expected to account for the largest share of the Asia–Pacific NGS market.
In 2025, China is expected to account for the largest share of the Asia–Pacific NGS market. The large share is primarily attributed to the increasing government focus on sequencing projects, the establishment of new healthcare facilities and modernizing existing ones, the large pool of patients with gene-associated disorders, and growing research activities for developing personalized medicines.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 6.38 billion |
| CAGR (2025–2032) | 16.9% |
| Format | PDF, Excel & Cloud Portal · 200 pages |
| Segments Covered | By Offering: Library Preparation & Target Enrichment, Quality Control · By Sequencing Type: Targeted Genome Sequencing, Whole Genome Sequencing, Whole Exome Sequencing · By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing (SMRT), Nanopore Sequencing · By Application: Research Applications Drug Discovery, Agriculture & Animal Research, Other Research Applications, Reproductive Health Diagnosis, Oncology, Infectious Diseases, Other Clinical Applications · By End User: Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic Institutes & Research Centers, Other End Users · By Type: Genome, Exome, Targeted |
| Countries Covered | Asia-Pacific (RoAPAC) |
| Key Companies | Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd, PerkinElmer, Inc., Agilent Technologies, Inc., California Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., Genomics, Inc. |
Report overview
Segments covered: offering, sequencing type, technology, application, end user, type. Regions: Asia-Pacific.
Next Generation Sequencing (NGS) is a technology used to sequence the orientation of nucleotides in genetic material. This technology enables the sequencing of DNA or RNA more quickly and at a lower cost compared to Sanger sequencing. Continuous developments in NGS technology are revolutionizing the field of personalized medicine, genetic diseases, and clinical diagnostics by providing the capability to sequence multiple individuals with a variable genetic orientation simultaneously.
The growth of this market is driven by factors such as the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing procedures, and increasing pharmaceutical R&D expenditures. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.
Additionally, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to offer significant market growth opportunities. However, the lack of skilled professionals and regulatory and standardization concerns in diagnostic testing pose a significant challenge to the market's growth.
Report infographic
-Market.webp)
Market dynamics
1 factors across 1 forceThe Increasing Applications of NGS Create an Opportunity for the Market
NGS has gained much significance in clinical practices for oncology, reproductive health, Mendelian disorders, complex diseases, and infectious diseases. In the coming years, NGS is expected to diversify in other clinical areas, with a considerable reduction in sequencing costs. The technology is expected to show substantial penetration in applications such as liquid biopsies for the early detection and monitoring of cancer and reproductive health applications. New biomarkers and actionable mutations are being identified by researchers, which are consequently expected to increase the applications and usage of NGS technology, creating growth opportunities for the players operating in the NGS market.
Table of contents
13 chapters · 100 sections · 200 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Consumables | — |
| By Sequencing Type | Targeted Genome Sequencing | — |
| By Technology | Sequencing by Synthesis | — |
| By End User | Pharmaceutical & Biotechnology Companies | — |
By Offering
- The consumables segment is expected to account for the largest share of the Asia–Pacific NGS market by offering.
- The recurring use of consumables, rising demand for NGS-based diagnostic tests, and increasing applications of NGS in oncology, reproductive health diagnosis, and drug discovery are increasing the demand for consumables.
By Sequencing Type
- The targeted genome sequencing segment is expected to account for the largest share of the NGS market in 2025.
- The large share of this segment is attributed to rapid and cost-effective methods, applications in discovering somatic mutations in complex samples such as cancerous tumors mixed with germline DNA, and a high cult of researchers for targeted genome sequencing to study gene-drug associations is expected to drive the targeted genome sequencing segment.
By Technology
- The sequencing by synthesis segment is expected to account for the largest share of the Asia–Pacific NGS market.
- The key factors supporting the large market share of this segment are highly accurate output with base-by-base sequencing using sequencing by synthesis, reducing sequence-specific errors, and enabling robust base calling across the entire genome, including repetitive sequences and homopolymers.
By End User
- The pharmaceutical & biotechnology segment is expected to account for the largest share of the Asia–Pacific NGS market.
- The large market share of this segment is attributed to factors such as the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of chronic diseases, which drive the adoption of NGS among pharmaceutical & biotechnology companies.
Geographic analysis
Asia-Pacific
Largest shareIn 2025, China is expected to account for the largest share of the Asia–Pacific NGS market. The large share is primarily attributed to the increasing government focus on sequencing projects, the establishment of new healthcare facilities and modernizing existing ones, the large pool of patients with gene-associated disorders, and growing research activities for developing personalized medicines. China to Account for the Largest Market Share in 2025
Competitive landscape
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- F. Hoffmann-La Roche Ltd
- PerkinElmer, Inc.
- Agilent Technologies, Inc.
- California Inc.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Genomics, Inc.
Frequently asked questions
This study offers a detailed assessment of the Asia-Pacific NGS market, including the market size & forecast for various segmentations like offering, sequencing type, technology, application, and end user. This report also involves the value analysis of various segments and sub-segments of NGS at the country level.
Cite this report
Meticulous Research. (2025). Asia-Pacific Next Generation Sequencing (NGS) Market - Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041039). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/asia-pacific-next-generation-sequencing-market-5722